Stifel Cuts Outset Medical Price Target to $8, Keeps Buy Rating
Stifel analyst Rick Wise cut Outset Medical’s price target to $8 from $14 while maintaining a Buy rating, citing near-term pressures in the MedTech sector. Outset posted Q3 2025 revenue of $29.4 million, up 3% year-over-year, and raised full-year guidance to $115–120 million.
1. Price Target Cut by Stifel
On January 7, Stifel analyst Rick Wise reduced Outset Medical’s price target from $14 to $8 while maintaining a Buy rating. The revision reflects anticipated near-term headwinds in the MedTech industry following 2025.
2. Q3 2025 Financial Highlights
In Q3 2025, Outset Medical reported revenue of $29.4 million, a 3% year-over-year increase. Tablo console sales rose 8%, and management raised full-year 2025 revenue guidance to a range of $115 million to $120 million.
3. Sector Outlook and Implications
Despite the price target reduction, the analyst remains constructive on MedTech trends for 2026, citing strong adoption of dialysis solutions. The updated valuation underscores both the stock’s growth potential and sensitivity to near-term sector pressures.